RASi-resistant in vitro and in vivo models of murine and human PDAC are generated to inform the development of more effective combination strategies for PDAC by defining resistance mechanisms and revealing therapeutic vulnerabilities, with potential implications for translational efforts in a disease with significant unmet clinical need.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, due in large part to limited therapeutic options and the rapid emergence of treatment resistance. Despite the clinical success of recently developed RAS inhibitors (RASi) resistance to these agents , both mutant-specific and pan-RAS, emerges rapidly, limiting their long-term efficacy. Here, we generated RASi-resistant in vitro and in vivo models of murine and human PDAC. Resistance mechanisms were characterized in vitro using RNA sequencing and phospho-proteomics, and in vivo using spatial transcriptomics. Across these models, we identified convergent mechanisms of resistance, including shared features between mutant-specific and pan-RAS inhibitor-resistant models. Notably, combination strategies that are effective in treatment-naïve models lose efficacy once RASi resistance has emerged. Together, these findings inform the development of more effective combination strategies for PDAC by defining resistance mechanisms and revealing therapeutic vulnerabilities, with potential implications for translational efforts in a disease with significant unmet clinical need.
Vasiliki Pantazopoulou, Casie Kubota, Woncheol Jung, Satoshi Ogawa, Kassidy Curtis, Araceli Herrera Morales, Hyemin Song, Tae Gyu Oh, Dannielle Engle. Exploring combination therapies to overcome RAS inhibitor resistance in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B063.
This study defines adaptive resistance mechanisms to KRAS-targeted therapy in PDAC, revealing both cell-state-dependent RTK rewiring and a conserved SFK adaptive signaling axis and provides a mechanistic rationale for either KRAS/pan-RAS or pan-RAS/SFK co-inhibition as strategies to improve responses to KRAS-targeted t...
Qing-Xiang Lin, Bo-Kai Song, C. Sander et al.· Cancer Research· 1 citation
The findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition, and may represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients.
G. Outeiro-Pinho, Aref Hosseini, Maciej Garczyk et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancer types in the United States, with over 90% of tumors driven by oncogenic KRAS. Several KRAS inhibitors have demonstrated promising preclinical or early clinical efficacy; however, their therapeutic benefit is limited by the emergence of acquired...
Saurabh Mandal, M. Bharmal, Swathi Sridhar et al.· Cancer Research· 0 citations
Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...
T. McFall, Daniel Dorbin, Julia R. Herrera et al.· Cancer Research· 0 citations
Despite decades of intensive research, pancreatic cancer remains one of the deadliest malignancies, with only modest improvements in patient survival. Recently, important clinical breakthroughs have been achieved with inhibitors targeting the active RAS(ON) state, doubling the median overall survival of patients...
J. Bruun, P. Eide, C. A. Andreassen et al.· Cancer Research· 0 citations
Current knowledge on molecular resistance to RAS-directed inhibitors in PDAC is summarized, organized into five categories: intrinsic resistance, KRAS-dependent mechanisms, KRAS-independent bypass signaling, downstream pathway reactivation, and tumor microenvironment (TME)-mediated resistance.
M. Pagano Mariano, Enrica Sgarilli, Dirk Mijnlieff et al.· Cancer Drug Resistance· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.